세계의 세포치료 기술 시장 : 제품, 치료 유형, 제조 공정, 전달 방법, 용도, 최종사용자별 - 예측(2025-2030년)

The Cell Therapy Technologies Market was valued at USD 4.66 billion in 2024 and is projected to grow to USD 5.29 billion in 2025, with a CAGR of 14.05%, reaching USD 10.25 billion by 2030.

The field of cell therapy technologies has rapidly emerged as a cornerstone of modern medical innovation, enabling transformative treatments in regenerative medicine and oncology. This market is witnessing an influx of groundbreaking scientific discoveries and a surge in investments that are redefining the boundaries of traditional therapeutic approaches. As industry stakeholders navigate increasingly complex regulatory environments and manage escalating patient expectations, the need for robust market insights has never been greater.

Recent advancements in laboratory techniques, manufacturing processes, and quality control methodologies have paved the way for the commercialization of novel cell-based treatments. Driven by both public and private sector investments, the ecosystem is evolving at a breakneck pace. This analytical overview encapsulates the innovative spirit of cell therapy technologies while providing a detailed examination of pivotal factors such as market segmentation, geographic trends, and leading industry players. The discussion that follows is designed to furnish decision-makers with a balanced, fact-based understanding of trends, opportunities, and challenges in this dynamic landscape.

Transformative Shifts Reshaping the Cell Therapy Technologies Landscape

In recent years, transformative shifts have redefined the cell therapy technologies landscape, driven by a confluence of scientific innovation, strategic investment, and evolving regulatory frameworks. Emerging technologies in bioprocessing and automation have revolutionized manufacturing, leading to improved efficiency and scalability. In addition, digital advancements are now playing a critical role in integrating data-driven insights with traditional lab-based approaches, thereby enabling more precise therapies and ensuring rigorous quality control.

Market dynamics are also reshaped by cross-disciplinary collaborations, with academic institutions and biopharmaceutical companies pooling resources and expertise to fast-track breakthroughs. Regulatory agencies across various regions have introduced forward-thinking policies that not only safeguard patient safety but also promote accelerated pathways to market. These progressive shifts are complemented by a growing consumer demand for therapies that are personalized and minimally invasive. Together, these factors signal an industry transitioning from experimental treatments to widely accessible, highly effective therapeutic solutions. The interplay between innovation, regulation, and market demand continues to sculpt the landscape, providing an environment ripe for disruptive growth and transformative potential.

Key Segmentation Insights in the Cell Therapy Technologies Market

An in-depth exploration of the market reveals critical segmentation dimensions that provide insights into the diverse categorizations within cell therapy technologies. When analyzed based on offering, the market is categorized into consumables, equipment, and software and services, where equipment itself is divided into bioreactors and cell analyzers, and software and services further bifurcate into data management and quality control. This layered segmentation underscores the multifaceted nature of supply chains and the integration of digital solutions with traditional hardware in driving market advancement.

Further segmentation by therapy type distinguishes between allogeneic cell therapy, autologous cell therapy, and gene-modified cell therapy. Detailed analysis shows that allogeneic cell therapy branches out into dendritic cells, induced pluripotent stem cells, and natural killer cells, while autologous cell therapy covers hematopoietic stem cells, mesenchymal stem cells, and T-cells. Gene-modified cell therapy refines the market further into CAR-T cell therapy and TCR therapy, highlighting the interplay between genetic engineering and personalized medicine.

Additional segmentation is observed in the manufacturing process, where distinctions are made across cell culture, cell expansion, and cell separation; cell culture is split into 2D and 3D culture systems, cell expansion into adherent and suspension cultures, and cell separation into fluorescence-activated cell sorting and magnetic-activated cell sorting. Analysis based on delivery method differentiates between ex vivo and in vivo approaches, and segmentation by application categorizes market opportunities in cardiovascular disease, musculoskeletal disorders, neurodegenerative diseases, and oncology, with further sub-categories providing a nuanced overview. Finally, segmentation by end user encompasses biopharmaceutical companies, hospitals - further analyzed into private and public segments - and research institutes, which include government research centers and universities. These insights offer a detailed roadmap for tailoring strategies that cater to the specific needs of each segment, thus ensuring targeted growth and optimized resource allocation.

Based on Offering, market is studied across Consumables, Equipment, and Software & Services. The Equipment is further studied across Bioreactors and Cell Analyzers. The Software & Services is further studied across Data Management and Quality Control.

Based on Therapy Type, market is studied across Allogeneic Cell Therapy, Autologous Cell Therapy, and Gene-Modified Cell Therapy. The Allogeneic Cell Therapy is further studied across Dendritic Cells, Induced Pluripotent Stem Cells, and Natural Killer Cells. The Autologous Cell Therapy is further studied across Hematopoietic Stem Cells, Mesenchymal Stem Cells, and T-Cells. The Gene-Modified Cell Therapy is further studied across CAR-T Cell Therapy and TCR (T-Cell Receptor) Therapy.

Based on Manufacturing Process, market is studied across Cell Culture, Cell Expansion, and Cell Separation. The Cell Culture is further studied across 2D Culture Systems and 3D Culture Systems. The Cell Expansion is further studied across Adherent Culture and Suspension Culture. The Cell Separation is further studied across Fluorescence-Activated Cell Sorting and Magnetic-Activated Cell Sorting.

Based on Delivery Method, market is studied across Ex vivo and In vivo.

Based on Application, market is studied across Cardiovascular Disease, Musculoskeletal Disorders, Neurodegenerative Diseases, and Oncology. The Cardiovascular Disease is further studied across Ischemic Heart Disease and Peripheral Artery Disease. The Musculoskeletal Disorders is further studied across Osteoarthritis and Rheumatoid Arthritis. The Neurodegenerative Diseases is further studied across Alzheimer's Disease and Parkinson's Disease. The Oncology is further studied across Hematological Cancer and Solid Tumors. The Solid Tumors is further studied across Breast Cancer, Lung Cancer, and Prostate Cancer.

Based on End User, market is studied across Biopharmaceutical Companies, Hospitals, and Research Institutes. The Hospitals is further studied across Private Hospitals and Public Hospitals. The Research Institutes is further studied across Government Research Centers and University Academics.

Key Regional Trends Driving Global Market Dynamics

The global cell therapy technologies market is experiencing region-specific trends that highlight diverse adoption patterns and investment priorities. In the Americas, there is a robust focus on capitalizing on fast-paced innovation alongside a well-established regulatory framework that supports rapid market entry and commercialization. Europe, the Middle East & Africa exhibit a blend of regulatory stringency and emerging market opportunities, with research and healthcare institutions driving early-stage clinical developments and technology integration. Meanwhile, the Asia-Pacific region has emerged as a fertile ground for scaling innovations, offering extensive support for research collaborations and a surge in infrastructure investments that facilitate local manufacturing and quality control advancements.

These regional insights reflect varied yet interconnected approaches to implementing cell therapy solutions across different healthcare ecosystems. By recognizing the strategic strengths of each region, stakeholders can better align their investment and operational strategies to tap into localized opportunities while balancing broader global trends. Careful consideration of these geographical factors is essential for optimizing market entry strategies and ensuring sustainable long-term growth.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insights on Leading Companies Shaping the Future of Cell Therapy Technologies

Several key players have emerged as frontrunners in the cell therapy technologies space, driving innovations that are reshaping the therapeutic landscape. Companies such as Adaptimmune Limited, Allogene Therapeutics Inc., and Atara Biotherapeutics, Inc. are at the forefront of developing pioneering treatments, leveraging advancements in cellular engineering and process optimization. Notably, Bellicum Pharmaceuticals, Inc. and Bluebird Bio Inc. have carved a niche with their focus on next-generation immunotherapies, while Cellectis SA and Century Therapeutics, Inc. are redefining manufacturing techniques to ensure scalability and clinical efficacy.

Other leading companies, including Charles River Laboratories International, Inc., ElevateBio LLC, and Gamida Cell Ltd., have been instrumental in providing comprehensive R&D and manufacturing support, thus facilitating innovative breakthroughs across the board. The integrated contributions of GE HealthCare Technologies Inc., Gilead Sciences, Inc., and Iovance Biotherapeutics, Inc. further highlight an established commitment to improving patient outcomes through state-of-the-art technologies. Moreover, industry giants such as Johnson & Johnson Services, Inc. and Legend Biotech USA Inc. continue to invest in clinical trials and strategic partnerships, while Novartis AG, Sartorius AG, and STEMCELL Technologies Inc. drive operational excellence through rigorous process improvements. The impactful endeavors of Takara Bio Inc., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., and Vericel Corporation collectively illustrate the sector's momentum toward transformative therapeutic solutions.

The report delves into recent significant developments in the Cell Therapy Technologies Market, highlighting leading vendors and their innovative profiles. These include Adaptimmune Limited, Allogene Therapeutics Inc., Atara Biotherapeutics, Inc., Bellicum Pharmaceuticals, Inc., Bluebird Bio Inc., Cellectis SA, Century Therapeutics, Inc., Charles River Laboratories International, Inc., ElevateBio LLC, Gamida Cell Ltd., GE HealthCare Technologies Inc., Gilead Sciences, Inc., Iovance Biotherapeutics, Inc., Johnson & Johnson Services, Inc., Legend Biotech USA Inc., Novartis AG, Sartorius AG, STEMCELL Technologies Inc., Takara Bio Inc., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., and Vericel Corporation. Actionable Recommendations for Industry Leaders in Cell Therapy Technologies

For decision-makers and strategists poised to capitalize on the evolving opportunities in the cell therapy technologies market, several actionable recommendations stand out. Firstly, leaders should prioritize investment in research and development initiatives that emphasize scalability and process optimization, ensuring that emerging trends in manufacturing and digital integration are fully leveraged. Embracing collaborative models that incorporate partnerships between technological innovators, therapeutic developers, and clinical researchers can further expedite product development and market entry.

It is also imperative to enhance regulatory compliance frameworks by staying current with evolving global standards, particularly those concerning quality control and data integrity. By instituting rigorous internal protocols and adopting state-of-the-art process monitoring systems, companies can mitigate risks and maintain competitive advantages in a rapidly evolving environment. Additionally, fostering strong regional partnerships is crucial; tailoring strategies to market-specific needs in areas such as the Americas, Europe, Middle East & Africa, and Asia-Pacific will drive targeted growth and better resource allocation.

Finally, building robust portfolios that align product offerings across consumables, equipment, and integrated software and services can help maximize value across end user populations. Industry leaders should consistently re-evaluate market segmentation insights to identify emerging niche opportunities and adjust investment priorities accordingly. A proactive, multi-dimensional approach is essential for harnessing the full potential of this transformative market.

Conclusion: Charting the Course for Future Innovation in Cell Therapy Technologies

In summary, the multifaceted nature of the cell therapy technologies market presents both unprecedented opportunities and complex challenges. From a comprehensive review of segmentation facets-including offerings, therapy types, manufacturing processes, delivery methods, and end-user applications-to a detailed examination of regional trends and key industry players, it is evident that the market is poised for significant transformation. By synthesizing insights drawn from diverse dimensions of technological innovation, regulatory evolution, and market dynamics, stakeholders can develop tailored strategies that capture incremental value and drive long-term growth.

As the industry continues to evolve, it is crucial for companies to remain agile and responsive to emerging trends, ensuring that their innovation pipelines and operational strategies are in sync with the rapidly changing landscape. The insights presented in this analysis provide a clear roadmap for navigating the complex interplay of challenges and opportunities, ultimately laying the foundation for a future characterized by enhanced therapeutic impact and improved patient outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing awareness and acceptance among patients regarding personalized medicine solutions
    • 5.1.1.2. Increasing prevalence of chronic and genetic disorders worldwide
    • 5.1.1.3. Rising government and private funding support for research and development initiatives
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with cell therapy technologies
  • 5.1.3. Opportunities
    • 5.1.3.1. Integrating cell therapies with pharmaceutical innovations to address unmet medical needs
    • 5.1.3.2. Growing partnerships between biotech companies and healthcare institutions for cell therapy innovations
  • 5.1.4. Challenges
    • 5.1.4.1. Difficulty in recruiting and retaining patients for clinical trials
• 5.2. Market Segmentation Analysis
  • 5.2.1. Therapy Type: Rising utilization of autologous cell therapy to minimize the risk of immune rejection
  • 5.2.2. Application: Rising application of cell therapy technologies in cardiovascular diseases to enhance angiogenesis and repair myocardial tissue
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cell Therapy Technologies Market, by Offering

• 6.1. Introduction
• 6.2. Consumables
• 6.3. Equipment
  • 6.3.1. Bioreactors
  • 6.3.2. Cell Analyzers
• 6.4. Software & Services
  • 6.4.1. Data Management
  • 6.4.2. Quality Control

7. Cell Therapy Technologies Market, by Therapy Type

• 7.1. Introduction
• 7.2. Allogeneic Cell Therapy
  • 7.2.1. Dendritic Cells
  • 7.2.2. Induced Pluripotent Stem Cells
  • 7.2.3. Natural Killer Cells
• 7.3. Autologous Cell Therapy
  • 7.3.1. Hematopoietic Stem Cells
  • 7.3.2. Mesenchymal Stem Cells
  • 7.3.3. T-Cells
• 7.4. Gene-Modified Cell Therapy
  • 7.4.1. CAR-T Cell Therapy
  • 7.4.2. TCR (T-Cell Receptor) Therapy

8. Cell Therapy Technologies Market, by Manufacturing Process

• 8.1. Introduction
• 8.2. Cell Culture
  • 8.2.1. 2D Culture Systems
  • 8.2.2. 3D Culture Systems
• 8.3. Cell Expansion
  • 8.3.1. Adherent Culture
  • 8.3.2. Suspension Culture
• 8.4. Cell Separation
  • 8.4.1. Fluorescence-Activated Cell Sorting
  • 8.4.2. Magnetic-Activated Cell Sorting

9. Cell Therapy Technologies Market, by Delivery Method

• 9.1. Introduction
• 9.2. Ex vivo
• 9.3. In vivo

10. Cell Therapy Technologies Market, by Application

• 10.1. Introduction
• 10.2. Cardiovascular Disease
  • 10.2.1. Ischemic Heart Disease
  • 10.2.2. Peripheral Artery Disease
• 10.3. Musculoskeletal Disorders
  • 10.3.1. Osteoarthritis
  • 10.3.2. Rheumatoid Arthritis
• 10.4. Neurodegenerative Diseases
  • 10.4.1. Alzheimer's Disease
  • 10.4.2. Parkinson's Disease
• 10.5. Oncology
  • 10.5.1. Hematological Cancer
  • 10.5.2. Solid Tumors
    • 10.5.2.1. Breast Cancer
    • 10.5.2.2. Lung Cancer
    • 10.5.2.3. Prostate Cancer

11. Cell Therapy Technologies Market, by End User

• 11.1. Introduction
• 11.2. Biopharmaceutical Companies
• 11.3. Hospitals
  • 11.3.1. Private Hospitals
  • 11.3.2. Public Hospitals
• 11.4. Research Institutes
  • 11.4.1. Government Research Centers
  • 11.4.2. University Academics

12. Americas Cell Therapy Technologies Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Cell Therapy Technologies Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Cell Therapy Technologies Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Scenario Analysis
  • 15.3.1. Evotec and Novo Nordisk collaborate to advance off-the-shelf cell therapies
  • 15.3.2. CPC launches Aseptic Connector for enhanced cell and gene therapy cryopreservation
  • 15.3.3. Cellular Origins acquires Actia Platform IP to boost automated cell therapy manufacturing
• 15.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Adaptimmune Limited
• 2. Allogene Therapeutics Inc.
• 3. Atara Biotherapeutics, Inc.
• 4. Bellicum Pharmaceuticals, Inc.
• 5. Bluebird Bio Inc.
• 6. Cellectis SA
• 7. Century Therapeutics, Inc.
• 8. Charles River Laboratories International, Inc.
• 9. ElevateBio LLC
• 10. Gamida Cell Ltd.
• 11. GE HealthCare Technologies Inc.
• 12. Gilead Sciences, Inc.
• 13. Iovance Biotherapeutics, Inc.
• 14. Johnson & Johnson Services, Inc.
• 15. Legend Biotech USA Inc.
• 16. Novartis AG
• 17. Sartorius AG
• 18. STEMCELL Technologies Inc.
• 19. Takara Bio Inc.
• 20. Takeda Pharmaceutical Company Limited
• 21. Thermo Fisher Scientific Inc.
• 22. Vericel Corporation